Background: Peripheral neuropathy is a common side effect induced by chemotherapy agents like Cisplatin, Paclitaxel and Docetaxel. At present, there is no preventive strategy available against the development of neuropathy. This pilot study was performed to evaluate the feasibility of cold therapy and its impact on the incidence and severity of neuropathy induced by paclitaxel in a dose dense adjuvant regimen among patients with breast cancer. Methods: All adult female patients with early breast cancer planned to be treated with dose-dense schedule of Adriamycin, cyclophosphamide and Paclitaxel were eligible. Ice boot and glove were applied for the duration of all four Paclitaxel infusions on one side while the contralateral limbs were taken as control. Peripheral neuropathy was evaluated and graded prior to each Paclitaxel infusion and then at 3 and 6 months post treatment. Results: A total of 23 patients were recruited. Cold therapy was found to be feasible as no patient discontinued the ice glove and boot during Paclitaxel infusions. Neuropathy symptoms were observed more frequently and with higher grade of severity on control limbs compared to experimental side. There were 5 patients who were switched to ice glove and boot therapy after they developed peripheral neuropathy in the control limbs. These patients observed improvement in their symptoms subsequently. Conclusion: Cold therapy appears to be feasible and appears to have some potential to prevent Paclitaxel induced peripheral neuropathy in this pilot study. This role of cold therapy may be further explored and confirmed in future randomized trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.